PTX-SA-R

PTX-SA-R is an experimental metabolism-responsive small-molecule drug conjugate (SMDC) designed for the treatment of refractory solid tumors, including pancreatic cancer, glioblastoma, and lung cancer. The molecule consists of the cytotoxic agent paclitaxel (PTX) covalently linked to a choline moiety via a spacer. This configuration targets the choline transporter SLC44A1, which is significantly upregulated in various cancers, facilitating active cellular uptake. PTX-SA-R is amphiphilic and spontaneously self-assembles into micelles; for optimized delivery, it is often co-assembled with Solutol HS15 to form PTX-SA-R@HS15 micelles. These micelles utilize the enhanced permeability and retention (EPR) effect for passive tumor accumulation and exhibit pH-sensitive drug release within the acidic tumor microenvironment. Preclinical studies have demonstrated superior tumor accumulation, enhanced blood-brain barrier penetration, and potent antitumor activity in multiple xenograft models, including patient-derived xenografts (PDX).

Other names

PTXSAR